Results 21 to 30 of about 3,505 (170)
The Scientific World Journal, 2007 The objective of this study was to compare the therapeutic response of intravesical oxybutynin, propantheline, and capsaicin in the treatment of neurogenic detrusor overactivity.
Jacob George +5 more
doaj +1 more source
FUNCTIONAL DIAGNOSTICS OF LOWER URINARY TRACT IN CHILDREN
Slovenska pediatrija, 2023 Lower urinary tract dysfunction is clinically relevant because it may cause urinary tract infections, mainly due to accumulation of residual urine, adversely affect renal function, and may cause urine incontinence that strongly affects the child’s ...
Matjaž Kopač, Anamarija Meglič
doaj +1 more source
Advances in the Management of Neurogenic Detrusor Overactivity in Multiple Sclerosis [PDF]
International Journal of MS Care, 2013 Bladder dysfunction in multiple sclerosis (MS) can be socially disabling, have negative psychological and economic consequences, and impair patients' quality of life. Knowledge of the functional anatomy and physiology of the urinary tract is essential to understand the symptoms associated with central nervous system lesions and the pharmacotherapies ...
Gael J, Yonnet +3 more
openaire +2 more sources
Toxins, 2023 Spinal cord injuries (SCI) have a profound impact on autonomic systems, sometimes resulting in multi-organ dysfunction, including of the neurogenic bladder.
Po-Ming Chow, Hann-Chorng Kuo
doaj +1 more source
Therapeutic Advances in Urology, 2014 Control of the lower urinary tract is a complex, multilevel process that involves both the peripheral and central nervous system. Neurogenic lower urinary tract dysfunction (LUTD) is a widespread chronic illness that impairs millions of people worldwide.
Stephanie Knuepfer +1 more
doaj +1 more source
Systematic review of therapy for neurogenic detrusor overactivity [PDF]
Canadian Urological Association Journal, 2011 While many neurologic diseases predispose patients to neurogenicdetrusor overactivity (NDO), the only populations that have beensystematically studied are adults with multiple sclerosis (MS), adultswith spinal cord injury (SCI) and children and young adults withmyelodysplasia. First-line pharmacotherapy for NDO is an antimuscarinicdrug.
openaire +3 more sources
Detrusor Arreflexia as an End Stage of Neurogenic Bladder in HAM/TSP?
Case Reports in Medicine, 2011 The HTLV-1 virus is a known agent involved in the development of HAM/TSP. Past studies have typically observed patients with autonomic dysfunction consisting of detrusor overactivity and detrusor-sphincter dyssynergia, with the occasional observation of
Matheus Tannus +5 more
doaj +1 more source
Biomedicines, 2023 Neurogenic bladder dysfunction is a condition that affects both bladder storage and voiding function and remains one of the leading causes of morbidity after spinal cord injury (SCI).
Adam W. Doelman +4 more
doaj +1 more source
Current Directions in Biomedical Engineering, 2022 This research assesses the effect of tibial nerve electrical stimulation on urinary incontinence in individuals with spinal cord injury (SCI) being a prospective noncontrolled intervention study.
Tancredo Janaina +3 more
doaj +1 more source
Neurogenic Lower Urinary Tract Dysfunction in Asymptomatic Patients with Multiple Sclerosis
Biomedicines, 2022 Neurogenic lower urinary tract dysfunction (NLUTD) in asymptomatic patients with MS has been described in preliminary studies, but specific investigations of this topic are rare. Many authors advise early diagnosis and treatment of NLUTD in patients with
Anke K. Jaekel +9 more
doaj +1 more source